title: Effects of thalidomide on long-term bone marrow cultures from patients with myelodysplastic syndromes: induction of IL-10 expression in the stromal layers.
abstract: The purpose of this study was to investigate the in vitro effects of thalidomide on long-term bone marrow cultures from patients with myelodysplastic syndrome. We demonstrated that thalidomide induced an increase in granulocyte-macrophage colony forming unit numbers and in IL-10 expression. Thalidomide also promoted a slight increase in IL-6, IL-1β and TNF-α expression in the stromal layers. The numbers of erythroid burst forming units, the apoptosis rate of hematopoietic cells, and VEGF and TNF-α expression levels in culture supernatants were not modulated. Our results indicate a participation of thalidomide upon the hematopoietic microenvironment of patients with myelodysplastic syndromes, especially in the up regulation of IL-10.
authors.affiliation: Hematology and Hemotherapy Center, School of Medical Sciences, University of Campinas, HEMOCENTRO-UNICAMP, Campinas, SP, Brazil. marilazarini@gmail.com
authors.forename: Mariana
authors.initials: M
authors.lastname: Lazarini
authors.forename: Fabíola
authors.initials: F
authors.lastname: Traina
authors.forename: Sheila M
authors.initials: SM
authors.lastname: Winnischofer
authors.forename: Fernando F
authors.initials: FF
authors.lastname: Costa
authors.forename: Mary Luci S
authors.initials: ML
authors.lastname: Queiroz
authors.forename: Sara T Olalla
authors.initials: ST
authors.lastname: Saad
mesh_terms: D000328:Adult; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D001853:Bone Marrow / Q000187:drug effects*; D018920:Coculture Techniques; D003114:Colony-Forming Units Assay; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006412:Hematopoietic Stem Cells; D006801:Humans; D016753:Interleukin-10 / Q000235:genetics / Q000378:metabolism*; D053583:Interleukin-1beta / Q000235:genetics / Q000378:metabolism; D015850:Interleukin-6 / Q000235:genetics / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism*; D012333:RNA, Messenger / Q000235:genetics; D020133:Reverse Transcriptase Polymerase Chain Reaction; D017154:Stromal Cells / Q000187:drug effects* / Q000378:metabolism; D013792:Thalidomide / Q000627:therapeutic use*; D014409:Tumor Necrosis Factor-alpha / Q000235:genetics / Q000378:metabolism; D042461:Vascular Endothelial Growth Factor A / Q000235:genetics / Q000378:metabolism
chemical_list: D020533:Angiogenesis Inhibitors; D053583:Interleukin-1beta; D015850:Interleukin-6; D012333:RNA, Messenger; D014409:Tumor Necrosis Factor-alpha; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D016753:Interleukin-10; D013792:Thalidomide